新辅助化疗后保留乳头乳晕乳房切除与即刻重建的肿瘤学结局
该回顾性研究纳入310例(319侧)接受新辅助化疗后行保留乳头乳晕乳房切除并即刻重建的乳腺癌患者,中位随访63±22个月,5年累积局部区域复发率为11.0%、乳头乳晕复发率为1.9%。多因素分析显示新辅助化疗后Ki67≥10%是局部区域复发的独立危险因素(HR 4.245,95%CI 1.865-9.663,P=0.001)。
要点
- 新辅助化疗后NSM+即刻重建的5年LRR为11.0%、NR为1.9%。
- 新辅助化疗后Ki67≥10%是LRR独立危险因素(HR 4.245)。
- 对新辅助化疗后Ki67≥10%者需谨慎随访。
核心结论
- 对经适当选择的接受新辅助化疗的乳腺癌患者,保留乳头乳晕乳房切除与即刻重建的肿瘤学安全性可接受,局部区域复发率和乳头乳晕复发率均在可接受范围。
- 新辅助化疗后Ki67≥10%与局部区域复发或乳头乳晕复发风险增加相关,需谨慎随访。
研究设计与样本
- 回顾性分析2010年2月至2016年11月间310例(319侧乳房)接受新辅助化疗后行保留乳头乳晕乳房切除的乳腺癌患者。
- 采用单因素(卡方或Fisher精确检验)和多因素(Cox比例风险回归模型)分析局部区域复发和乳头乳晕复发的危险因素。
主要发现
- 平均随访63±22个月,38例以局部区域复发为首发事件,其中6例以乳头乳晕复发为首发事件。
- 5年累积局部区域复发率为11.0%,乳头乳晕复发率为1.9%。
- 单因素分析中,临床T分期、病理淋巴结状态、组织学分级、脉管侵犯和新辅助化疗后Ki67状态与局部区域复发风险增加相关;新辅助化疗后Ki67状态是乳头乳晕复发的唯一显著危险因素。
- 多因素分析中,新辅助化疗后Ki67≥10%是局部区域复发的独立危险因素(风险比4.245;95%置信区间1.865-9.663;P=0.001)。
临床怎么用
- 对于接受新辅助化疗后考虑保留乳头乳晕乳房切除与即刻重建的乳腺癌患者,应评估新辅助化疗后Ki67状态以辅助风险分层。
- 新辅助化疗后Ki67≥10%的患者局部区域复发风险较高,需加强术后随访监测。
局限性
- 本研究为回顾性分析,可能存在选择偏倚。
- 样本来自单中心,随访时间有限,结论需更大队列验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the oncologic outcomes and risk factors for locoregional recurrence (LRR) and nipple-areola complex recurrence (NR) in a large series of breast cancer patients who underwent nipple-sparing mastectomy (NSM) and immediate reconstruction after neoadjuvant chemotherapy (NACT). SUMMARY OF BACKGROUND DATA: The use of NSM and immediate reconstruction in breast cancer patients receiving NACT is increasing. However, the oncologic safety of this approach is unclear. PATIENTS AND METHODS: A total of 310 breast cancer patients (319 breasts) who underwent NACT and NSM between February 2010 and November 2016 were retrospectively analyzed. Clinical and pathologic factors associated with increased risks of LRR and NR were analyzed using univariate (Chi-square or Fisher exact test) and multivariate (Cox proportional hazard regression model) analyses. RESULTS: During a mean follow-up of 63 ± 22 months, 38 cases had LRR as the first event, including 6 cases of NR as the first event. The 5-year cumulative LRR and NR rates were 11.0% and 1.9%, respectively. In univariate analysis, clinical T stage, pathologic nodal status, histologic grade, lymphovascular invasion, and post-NACT Ki67 status were associated with increased LRR risk, and post-NACT Ki67 status was the only significant risk factor for NR. In multivariate analysis, post-NACT Ki67 ≥10% (hazard ratio, 4.245; 95% confidence interval, 1.865-9.663; P = 0.001) was an independent risk factor for LRR. CONCLUSIONS: NSM and immediate reconstruction seem to be oncologically safe with acceptable LRR and NR rates for appropriately selected breast cancer patients treated with NACT. Post-NACT Ki67 ≥10% was associated with increased risk of LRR or NR, and therefore, necessitates cautious follow-up.
引用
- Wu ZY, Kim HJ, Lee JW, et al. Oncologic Outcomes of Nipple-sparing Mastectomy and Immediate Reconstruction After Neoadjuvant Chemotherapy for Breast Cancer. Ann Surg. 2021. PMID: 32209903. doi:10.1097/SLA.0000000000003798
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。